Transgenic Group (TSE:2342) Marketable Securities: 円0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:2342 Transgenic Group Inc TSE:2342
62 GF Score
Price 円256.00
GF Value 円255.79
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Transgenic Group Marketable Securities?

Transgenic Group TSE:2342 -1.16% 62 Marketable Securities is 円0 Mil as of Mar. 2026. GuruFocus rates TSE:2342 with a GF Score™ of 62/100 and a GF Value™ of 円255.79 (Fairly Valued). The stock has 4 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Transgenic Group's Marketable Securities for the quarter that ended in Mar. 2026 was 円0 Mil.

Transgenic Group  (TSE:2342) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Transgenic Group Marketable Securities Related Terms

Transgenic Group Marketable Securities Historical Data

* Premium members only.

The historical data trend for Transgenic Group's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Transgenic Group Marketable Securities Chart

Transgenic Group Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.96 0.00 0.00 0.00 0.00

Transgenic Group Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:2342
62GF Score
Transgenic Group Inc TSE:2342
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Transgenic Group Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of 円0 Mil mean?
Transgenic Group (TSE:2342) has a Marketable Securities of 円0 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Transgenic Group and its competitors.
Is Transgenic Group's Marketable Securities too high?
Transgenic Group's current Marketable Securities is 円0 Mil. Overall, Transgenic Group has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Transgenic Group's Marketable Securities compare to VRTX and REGN?
Transgenic Group's Marketable Securities of 円0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Transgenic Group and its competitors. Transgenic Group's current Marketable Securities is 円0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transgenic Group stock overvalued right now?
Based on GuruFocus' analysis, Transgenic Group (TSE:2342) is currently considered Fairly Valued. The stock's GF Value™ is 円255.79, compared to a current price of 円256.00 — trading 0.1% above its estimated fair value. The current Marketable Securities is 円0 Mil. Transgenic Group's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Transgenic Group (TSE:2342), the current Marketable Securities is 円0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Transgenic Group (TSE:2342) Overvalued in 2026?

Based on GuruFocus' analysis, Transgenic Group stock appears to be overvalued. The current stock price of 円256.00 is trading 0.1% above its estimated GF Value™ of 円255.79. GuruFocus considers Transgenic Group to be Fairly Valued.

Key valuation signals for TSE:2342:

  • Marketable Securities: 円0 Mil
  • GF Value™: 円255.79 vs. price of 円256.00 (0.1% above fair value)
  • GF Score™: 62/100 with 4 warning signs

No single metric tells the full story. See the TSE:2342 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Transgenic Group Business Description

Address 2-3-36 Tenjin, Chuo-ku, Fukuoka Prefecture, Fukuoka, JPN
Transgenic Group Inc formerly Trans Genic Inc is engaged in offering assistance of non-clinical experiments using large animals and general rearing management work, and non-clinical trial service using large animals. The company has two segments: Drug discovery support business, and Investment and consulting business.
62GF Score

Get the complete analysis for TSE:2342

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円256.00
Price
円255.79
GF Value